Sildenafil Tablet, Film Coated
Product Images NDC 68071-2072

8 FDA label images from Nucare Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-2072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

68071 2072 4

68071 2072 4
Packaging label for Sildenafil 20 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label states the product contains 4 round white/off-white tablets debossed with "C 89" on one side. It includes the NDC 68071-2072, storage instructions, warning to keep out of reach of children, and manufacturer information.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A forest plot chart showing the fold change and 90% confidence intervals for various interacting drugs on the accumulation ratios (AUC and Cmax) related to Sildenafil alone. The chart compares drugs including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, oral contraceptives, Ritonavir, and Saquinavir with corresponding recommendations for dose adjustment or coadministration. The x-axis represents the change relative to Sildenafil alone.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart showing the fold change and 95% confidence intervals of pharmacokinetic parameters (NR AUC and INR Cmax) for Sildenafil tablets at 20 mg strength when coadministered with various interacting drugs. The chart includes drugs such as Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin (1, 2, and 3 mg), Ethinylestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. Recommendations for dose adjustments are noted, mostly indicating no dose adjustment is necessary except for Ritonavir, which advises against coadministration or suggests no dose adjustment.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing the change from baseline in meters on the y-axis over a 12-week study period on the x-axis at weeks 4, 8, and 12. The graph compares four groups: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, each represented by distinct markers and lines with error bars indicating variability.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A forest plot figure comparing placebo versus Sildenafil 20 mg TID showing placebo-corrected changes in 6-minute walk distance across various subgroups including baseline walk distance, etiology, pulmonary hypertension functional class, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index. The horizontal axis measures distance change in meters, with confidence intervals displayed for each subgroup.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line graph depicting the percentage without a clinically worsening event over time from randomization, comparing two groups: Placebo and Sildenafil. The graph shows the percentage on the vertical axis and days from randomization on the horizontal axis, with Sildenafil represented by a dashed line and Placebo by a solid line, illustrating trends up to approximately 112 days.*
FDA Label Image

Sildenafil-citrate (Sildenafil Citrate)

Sildenafil-citrate (Sildenafil Citrate)
Chemical structure of Sildenafil showing its molecular framework with labeled functional groups and atoms as part of its chemical formula.*
FDA Label Image

Figure1 (Untitled)

Figure1 (Untitled)
A line graph depicting the estimated cumulative mortality rate (%) over time in years for three dosage groups labeled High Dose, Medium Dose, and Low Dose. The graph shows mortality increasing over approximately five years, with the High Dose group exhibiting the highest mortality rate and the Low Dose group the lowest. The number of subjects at risk for each group is displayed at multiple time points along the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.